Struggling Bioanalytical Systems adds outsider to board
Shareholders are starting to make inroads in their effort to turn struggling West Lafayette-based Bioanalytical Systems Inc. in a new direction.
Shareholders are starting to make inroads in their effort to turn struggling West Lafayette-based Bioanalytical Systems Inc. in a new direction.
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
Researchers at IUPUI have been awarded more than $22.3 million in grants by the National Institutes of Health, according to
U.S. Rep. Andre Carson. The money is part of a $5 billion program that was part of the federal stimulus bill approved earlier
this year, and will fund medical research across the country.
Indianapolis-based FAST Diagnostics, a developer of a method to quickly measure kidney function, announced today that it has
received $1 million in federal funding.
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
The pharmaceutical industry—which for two decades has given twice as much in campaign donations
to Republicans as Democrats—organized a panel composed mostly of Democrats this month in Indianapolis
to argue its position on health care reform.
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
Purdue University researcher Philip Low, also the chief science officer for West Lafayette-based Endocyte Inc., has developed
a prostate cancer “homing device” to help anti-cancer agents specifically target prostate
cancer tumors.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it’s developing a potential
competitor to Byetta all on its own.
Greenwood-based Elona Biotechnologies said it has created two subsidiaries to boost its biosimilar/biogeneric/follow-on protein
business.
Taking science from the laboratory to the commercial market takes too much time and is littered with potential pitfalls along the way.
In a state steeped in advanced research that spawns biomedical companies by the dozen, Apricity LLC is preposterously low-tech,
given that its latest product is nothing more than a warm blanket.
The Indiana chapter of the Arthritis Foundation works to improve lives through leadership in the prevention, control and cure
of arthritis and related diseases.
Indiana is becoming not only a hotbed of “pharmacogenomics” research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
Purdue University’s Student-Managed Venture Fund is betting its bank on West Lafayette-based biotech startup Kylin Therapeutics
Inc.
The stimulus bill has prompted Indiana businesses and not-for-profits that deal in medical records to look for partners to
help them meet the challenge of making those records electronic in five years.
The Indiana Chamber of Commerce has named Indianapolis-based health care research and testing firm AIT Laboratories its 2009
Small Business of the Year.
In January, St. Paul, Minn.-based 3M will release “Clinpro 5000,” a specialty toothpaste Indiana Nanotech developed.
If Indianapolis is going to be a first-class city, it needs to have a comprehensive smoke-free workplace law.